|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.65 USD | -4.74% |
|
-11.98% | +74.02% |
Nov 16 (Reuters) - Inovio Pharmaceuticals Inc said on Monday it had received the U.S. health regulator's clearance to begin a mid-stage study of its COVID-19 vaccine candidate, INO-4800.
The trial will be funded by the U.S. Department of Defense, the company said. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)
| 1st Jan change | Capi. | |
|---|---|---|
| +74.02% | 290M | |
| +17.96% | 47.02B | |
| +48.77% | 41.86B | |
| +1.17% | 41.76B | |
| -4.27% | 28.8B | |
| +11.42% | 26.05B | |
| -21.39% | 19.15B | |
| +4.86% | 12.55B | |
| +27.29% | 12.34B | |
| -3.50% | 11.82B |
INOVIO PHARMACEUTICALS, INC. 